Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

PROspect Registry :Post Market Clinical Follow-up Study

NCT07631468 · tracked via the Priya Life Science USA tracker
Phase
Observational
Started
2026-06-01
Last updated
2026-08-19

Condition(s) studied

Breast Surgery

Investigational drug(s) / intervention(s)

Standard of care treatment

Standard of care treatment: Subject has undergone breast surgical procedures using one of the study devices and meets eligibility criteria

Study summary

Retrospective, multi-center, chart review (only to include data that is part of the surgeons' standard practice)

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Subject was ≥ 18 years of age at the time of the surgery * Patients who have undergone breast surgical procedures using MOLLI, SPY-PHI, and/or SPY AGENT GREEN Exclusion Criteria: * Subjects who are less than 1-month post-intervention * Concurrent participation in an interventional investigational clinical study at the time of initial surgery * Subjects whose surgery date was prior to January 2022. * Pregnant or lactating females at the time of initial surgery

Primary outcome measure(s)

  • Successful marker localization — From the start of surgery to completion of surgery for each participant (assessed intraoperatively, up to the duration of the surgical procedure, typically within the same day)
    (proportion of MOLLI markers that are detected intraoperatively)
  • Marker retrieval success — From the start of surgery to completion of surgery for each participant (assessed intraoperatively, up to the duration of the surgical procedure, typically within the same day)
    (proportion of procedures in which the MOLLI marker is removed within the surgical specimen)

Trial sites (2)

FacilityCityRegionStatus
MD Baptist MD Anderson Jacksonville Florida Recruiting
Tufts Medical Center Boston Massachusetts Recruiting

More Stryker Endoscopy trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07631468 on ClinicalTrials.gov ↗ ← All trials in the USA